Koninklijke Philips (PHG)
(Real Time Quote from BATS)
$30.33 USD
-0.25 (-0.82%)
Updated Sep 23, 2024 10:36 AM ET
2-Buy of 5 2
A Value B Growth A Momentum A VGM
Price, Consensus and EPS Surprise
PHG 30.33 -0.25(-0.82%)
Will PHG be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for PHG based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PHG
Should Value Investors Buy Koninklijke Philips (PHG) Stock?
Why Royal Philips (PHG) is a Top Value Stock for the Long-Term
PHG: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Royal Philips (PHG) is a Top Value Stock for the Long-Term
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
Other News for PHG
Jackson Health System projects 47% reduction in carbon emissions from patient monitors with Philips next generation monitoring platform
Kepler Capital Remains a Buy on Koninklijke Philips N.V. (0LNG)
Vivos surges on FDA nod for pediatric sleep apnea device
Jefferies Reaffirms Their Sell Rating on Koninklijke Philips N.V. (0LNG)
Philips announces FDA approval for enhanced LumiGuide guidewire and marks the 1000th patient treated with its breakthrough 3D device guidance technology